Yuhan Corporation's Lazertinib and J&J's Amivantamab Combination Approved by FDA as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
FDA Approval Background and MARIPOSA Clinical Trial Results
Johnson & Johnson (J&J) and Yuhan Corporation's EGFR-mutated non-small cell lung cancer (NSCLC) treatment, Lazertinib (brand name: Lazrelu), in combination with Amivantamab (brand name: Libtyvio), received final approval from the U.S. FDA on August 19, 2024. This approval is based on the results of the global Phase 3 MARIPOSA trial, which demonstrated a 30% reduction in the risk of disease progression or death compared to the standard of care, AstraZeneca's Osimertinib (brand name: Tagrisso). The median progression-free survival (PFS) in the combination therapy group was 23.7 months, compared to 16.6 months in the Tagrisso monotherapy group, representing an extension of 7.1 months. Furthermore, at a median follow-up of 37.8 months, the overall survival (OS) hazard ratio was 0.75 (p-value = 0.005), demonstrating significant clinical benefit.
Mechanism of Action and Synergistic Dual Inhibition
The key to this combination therapy lies in the synergistic effect of Lazertinib, a third-generation oral EGFR tyrosine kinase inhibitor (TKI), and Amivantamab, a bispecific antibody targeting EGFR/MET. While Lazertinib blocks intracellular signaling, Amivantamab sterically inhibits receptors on the cell surface and induces immune attack. The two mechanisms are designed to complement each other to overcome the limitations of existing monotherapies, specifically resistance mutations. This dual-inhibition approach ensures greater depth and durability of treatment response compared to monotherapy.
Market Landscape Shift and Competition with Tagrisso
Currently, the global first-line treatment market for EGFR-mutated NSCLC is dominated by Tagrisso, with annual sales of $6.58 billion. The approval of the Lazertinib combination therapy is expected to disrupt this monopoly and reshape the market share. Although the initial intravenous formulation was considered a drawback, the approval of a subcutaneous formulation has significantly reduced this barrier. Based on the improved survival benefits without chemotherapy, the combination therapy is expected to rapidly increase in prescription preference among healthcare professionals.
Milestone in Domestic Bio R&D and Technology Export
This approval marks a significant milestone for the domestic pharmaceutical industry, as it is the first instance of a Korean-developed drug entering the global first-line treatment market. Yuhan Corporation licensed the compound from Oscotec in 2018 and subsequently out-licensed it to Janssen Biotech for a total of $950 million. With the global launch, milestone payments are being received continuously, contributing to Yuhan Corporation's financial stability. This is considered a successful model for sustainable research and development, going beyond a one-time drug development.
Based on Phase 3 clinical trial results, this FDA approval signifies the emergence of the first chemotherapy-sparing combination option that directly threatens AstraZeneca's Tagrisso monopoly in the $6.58 billion global EGFR-mutated NSCLC market. In the short term, Yuhan Corporation is expected to see a significant increase in its R&D investment resources through the receipt of a $60 million U.S. launch milestone payment and additional royalties upon approval in major countries. In the medium to long term, the continuous inflow of double-digit royalty revenues linked to global commercial sales will serve as a catalyst for establishing a sustainable growth model for the domestic pharmaceutical and biotechnology industry. Furthermore, the clinical data demonstrating a 30% reduction in the risk of disease progression and death compared to the Tagrisso monotherapy group (HR 0.70) and a 7.1-month extension in PFS will serve as a strong foundation for future market share gains.
Source: FDA Drug Approvals (rss)
http://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-lazcluze